• FSSAI & AYUSH Approved
  • WHO-GMP
  • ISO 9001:2015
  • PAN India
  • contact@3rdpartypharma.com
  • +91 9990906939
Free Quote
Best Injectable Manufacturer in India

Injection Manufacturing Company in Delhi

If you’ve been searching for a third party injectable manufacturing partner that treats sterility as non-negotiable, this is what that looks like — ampoules, vials, prefilled syringes and lyophilized injectables, manufactured in a WHO-GMP certified cleanroom facility with full aseptic process validation.
Get Free Quote
+91 9990906939
WhatsApp us

WHO-GMP

Certified

ISO 9001:2015

Certified

FSSAI

Approved

AYUSH

Approved

100%

Quality Assurance

10+

Product Categories

500+

Products

100+

Brands

10+

Years Experience

Sterile Injectable Manufacturer

Injectable manufacturing operates under a different risk category than almost any other dosage form we cover. A tablet with a minor defect gets caught by disintegration or dissolution testing before it ever reaches a patient. A contaminated injectable bypasses the body’s normal defense mechanisms entirely — it goes directly into the bloodstream. That’s why sterile injectable manufacturer facilities operate under a fundamentally stricter set of controls than solid or liquid oral manufacturing, and why cutting corners here isn’t a quality issue — it’s a patient safety issue.
Our injectable manufacturing facility in Delhi NCR runs aseptic processing under classified cleanroom conditions — ISO 7 and ISO 8 background environments with an ISO 5 critical filling zone — producing ampoules, vials, prefilled syringes, and lyophilized (freeze-dried) injectables under full WHO-GMP compliance. If you’ve been looking for injection manufacturing Company in Delhi NCR that applies this level of rigour as standard practice rather than a marketing claim, this is what the actual process looks like.
Whether you’re bringing an existing generic injectable formulation to market, launching a vitamin or mineral injectable, or need a third party injectable manufacturing partner for a specific therapeutic category — the manufacturing discipline and validation requirements apply at the same level regardless of order size.

Ampoule, Vial, Prefilled Syringe & Lyophilized — Injectable Formats Explained

Choosing the right injectable format isn’t a packaging decision made late in the process — it’s dictated by your active ingredient’s stability, the required dose volume, and how the product will actually be administered in clinical practice.

Ampoules

Single-use, sealed glass containers — the vial is broken open (snapped) for use, with no closure to fail. Common for single-dose injectables where the entire contents are used immediately. No preservative needed since there's no multi-dose access.

Vials

Glass or plastic containers sealed with a rubber stopper and aluminium crimp cap — accessed via needle through the septum. Available as single-dose or multi-dose (requiring a validated preservative system for the latter). More flexible dosing than ampoules.

Prefilled Syringes

Ready-to-inject format — no separate drawing-up step required. Reduces dosing error and administration time, increasingly preferred for self-administered or emergency-use injectables. Requires specialised filling equipment distinct from vial or ampoule lines.

A fourth category — lyophilized (freeze-dried) injectables — applies to any of the above container formats when the active ingredient isn’t stable in liquid solution over a normal shelf life. The product is filled as a liquid, then freeze-dried inside the final container, and reconstituted with a diluent immediately before administration. We cover this process in detail further down this page.

Aseptic Filling Manufacturer Process — Compounding to Seal

Raw Material and Water for Injection (WFI) Testing

Active ingredients and excipients undergo identity and purity testing. Water for Injection — the base solvent for most injectables — is tested for endotoxin levels and microbial content before any compounding begins. This single input, done wrong, compromises the entire batch.

Compounding in a Controlled Environment

The formulation is mixed in a classified area under controlled temperature, with in-process checks for pH, osmolarity, and assay before the batch moves toward sterilization.

Sterile Filtration

The compounded solution passes through a validated 0.22-micron sterilizing-grade filter — the step that actually removes microorganisms from a heat-sensitive formulation that can't be terminally sterilized. Filter integrity is tested before and after use to confirm no compromise occurred during filtration.

Aseptic Filling in an ISO 5 Zone

The sterile solution is filled into pre-sterilized ampoules, vials, or syringes within a Grade A / ISO 5 critical zone — the most tightly controlled environment in the facility, with continuous environmental monitoring for viable and non-viable particulate throughout the fill.

Sealing — Immediately After Filling

Ampoules are heat-sealed, vials are stoppered and crimp-capped, syringes are plunger-sealed — all within the same aseptic zone, without exposure to the surrounding environment between filling and closure.

100% Visual Inspection and Release Testing

Every single unit is visually inspected for particulate matter, container defects, and fill volume — not a statistical sample. Sterility testing, endotoxin testing, and potency assay are run on the batch before release. Certificate of Analysis issued only after all parameters clear.

Have an Injectable Formulation Ready to Manufacture?

Tell us your active ingredient, target format, and required MOQ — we’ll confirm feasibility, pricing, and lead time within 24 hours.
Call Now
Get Free Quote
WhatsApp us

Lyophilized Injectable Manufacturer — Freeze-Drying Process

Some active ingredients simply don’t survive in aqueous solution for a commercially viable shelf life — certain antibiotics and biologic-adjacent molecules degrade within days or weeks if left in liquid form. Lyophilization solves this by removing water from the formulation after filling, leaving a stable, porous cake that’s reconstituted with a diluent immediately before use.
As a lyophilized injectable manufacturer, our freeze-drying cycle runs in three stages: freezing the filled solution to a solid state, primary drying under vacuum (where the bulk of the water sublimates directly from solid to vapour without passing through liquid phase), and secondary drying to remove residual bound moisture. Getting the cycle parameters wrong produces cake collapse, uneven drying, or a product that doesn’t reconstitute cleanly — all of which fail quality release.
Because the product is exposed and vulnerable throughout the freeze-drying cycle — stoppers are only partially seated until the cycle completes, inside the lyophilizer chamber itself — this entire process happens within the aseptic zone, not in a separate, less controlled area. It’s one of the more technically demanding processes in sterile manufacturing, and one where experience genuinely matters.

Why Choose Us as Your Parenteral Manufacturing Company

ISO 5 aseptic zone — validated, not assumed

Our critical filling area meets Grade A / ISO 5 classification with continuous environmental monitoring, not periodic spot-checks. This is validated through documented particle counts, viable microbial monitoring, and airflow studies — available for your review before you commit to an order.

All four injectable formats under one facility

Ampoules, vials, prefilled syringes, and lyophilized injectables — you don't need to split your product range across multiple manufacturers based on format.

In-house sterility, endotoxin and particulate testing

Release testing doesn't wait on external lab turnaround. Our in-house microbiology and analytical labs run the full battery of tests, which means faster batch release without compromising on the rigour of any individual test.

Lyophilization cycle development experience

Freeze-drying cycles aren't a generic template applied to every product — cycle parameters are developed and validated specifically for your formulation's freezing point, collapse temperature, and moisture profile.

100% visual inspection, not statistical sampling

Every ampoule, vial, and syringe is inspected — not a representative batch sample. For a dosage form where a single particulate-contaminated unit is a real patient risk, this isn't optional practice.

WHO-GMP certified — consistent standard regardless of order size

Small first-order clients and established recurring brands get the same aseptic process, the same validation discipline, and a Certificate of Analysis with every batch. Sterility isn't a variable we adjust by order volume.

Quality Control and Sterility Testing

Injectable release testing has no equivalent leniency compared to other dosage forms — every parameter listed below runs on every batch, without exception, before a single unit is cleared for dispatch.
Test Parameter What It Confirms
Sterility Testing Absence of viable microorganisms — tested per pharmacopoeial method over a 14-day incubation period
Bacterial Endotoxin Testing (LAL) Endotoxin levels below the threshold that would trigger a pyrogenic reaction in the patient
Particulate Matter Testing Visible and sub-visible particles within pharmacopoeial limits — critical since particulates delivered intravenously pose real risk
Container Closure Integrity Testing Seal is intact and won't allow microbial ingress over the product's shelf life
Assay (Potency) Active ingredient content matches label claim within accepted limits
pH and Osmolarity Formulation compatible with body tissue — prevents injection site irritation or damage
Moisture Content (Lyophilized Products) Residual moisture within specification — affects reconstitution and long-term stability

WHO-GMP Certified Injectable Manufacturer — FAQ

MOQ for injectables is generally higher than other dosage forms because of the batch sizes required to justify aseptic line changeover and validation — typically starting from 10,000 to 25,000 units per SKU depending on the format. Prefilled syringes and lyophilized products may carry a higher minimum due to the specialised equipment and cycle development involved. If you’re evaluating feasibility for a smaller initial run, share your specifics and we’ll confirm what’s realistic.
It depends on dosing requirements, administration setting, and whether multi-dose access is needed. Single-dose, immediate-use products often suit ampoules. Products needing multi-dose flexibility or a preservative system work well as vials. Products intended for rapid or self-administration — particularly in emergency or home-use settings — are increasingly moving to prefilled syringes. Tell us your active ingredient and intended use case and we’ll recommend the right format.
Yes — lyophilization is available for formulations that aren’t stable in liquid form over a commercial shelf life. This requires cycle development specific to your formulation’s physical and chemical properties, which adds time to the first production run compared to a standard liquid-fill injectable. Once the cycle is validated, repeat batches follow the established parameters and move faster.
Our aseptic manufacturing process is validated to achieve a Sterility Assurance Level (SAL) of 10⁻⁶ — the pharmacopoeial standard for aseptically processed sterile products, meaning the probability of a single unit being non-sterile is one in a million. This is confirmed through routine sterility testing on every batch plus periodic media fill validation of the aseptic process itself.
For an existing formulation with approved documentation, typically 30 to 45 working days from order confirmation to dispatch — longer than most other dosage forms because of the extended release testing cycle (sterility testing alone requires a 14-day incubation period). Lyophilized products and new formulations requiring cycle development add further time. Repeat orders on validated formulations move faster once the process is established.

Get a Manufacturing Quote

Ready to launch your own brand?

  • Free Consultation
  • Low MOQ Available
  • Response in 30 Minutes